28 February 2025 in Research Integrity and Peer Review
Background: Artificial intelligence (AI) chatbots are novel computer programs that can generate text or content in a natural language format. Academic publishers are adapting to the transformative role of AI chatbots in producing or facilitating scientific research. This study aimed to examine the policies established by scientific, technical, and medical academic publishers for defining and regulating the authors’ responsible use of AI chatbots. Methods: This study performed a cross-sectional audit on the publicly available policies of 162 academic publishers, indexed as members of the International Association of the Scientific, Technical, and Medical Publishers (STM). Data extraction of publicly available policies on the webpages of all STM academic publishers was performed independently, in duplicate, with content analysis reviewed by a third contributor (September 2023—December 2023). Data was categorized into policy elements, such as ‘proofreading’ and ‘image generation’. Counts and percentages of ‘yes’ (i.e., permitted), ‘no’, and ‘no available information’ (NAI) were established for each policy element. Results: A total of 56/162 (34.6%) STM academic publishers had a publicly available policy guiding the authors’ use of AI chatbots. No policy allowed authorship for AI chatbots (or other AI tool). Most (49/56 or 87.5%) required specific disclosure of AI chatbot use. Four policies/publishers placed a complete ban on the use of AI chatbots by authors. Conclusions: Only a third of STM academic publishers had publicly available policies as of December 2023. A re-examination of all STM members in 12–18 months may uncover evolving approaches toward AI chatbot use with more academic publishers having a policy.
30 March 2026 in Nature Communications
The role of the cohesin complex depends on the cohesin loader proteins NIPBL and MAU2. While NIPBL variants are a major cause of Cornelia de Lange Syndrome (CdLS), the role of MAU2 in disease is unclear. We describe 18 individuals carrying 15 heterozygous MAU2 variants and demonstrate pathogenicity through functional analyses. In-frame MAU2 variants predominantly impair NIPBL–MAU2 interaction, whereas truncating variants cause MAU2 haploinsufficiency and lead to NIPBL reduction. Most individuals exhibit a DNA methylation profile compatible with the CdLS episignature. We also describe two MAU2 -specific episignatures that reflect variant-dependent molecular consequences. Affected individuals display a wide range of phenotypes, from classic CdLS to milder presentations, with short stature and microcephaly as major features. A heterozygous Mau2 knockout mouse model recapitulates these traits, confirming the causal role of MAU2 disruption in vivo. Our study establishes MAU2 as a CdLS-associated gene and delineates a MAU2 -related chromatinopathy with variable expressivity.